More on SRPT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $22.02 |
|
|||
| Open | $22.02 | ||||
| 52 Wk High | $63.73 | ||||
| 52 Wk Low | $8.00 | ||||
| Day High | $22.02 | ||||
| Day Low | $20.28 | ||||
| P/E | N/A | ||||
| EPS | $-5.69 | ||||
| Volume | 2,203,934 | ||||
- H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
- Jefferies: 'we can still see at least a +25-50% stock move if SRPT shows competitive/superior 6-month splicing/vHOT data'
- Mizuho Defends Sarepta Therapeutics (SRPT)
- Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
- Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Form 13F-HR Sarepta Therapeutics, For: Jun 30
- Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC
- Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP
- Sarepta Therapeutics (SRPT) PT Lowered to $35 at Oppenheimer
- Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue
Entities mentioned with SRPT
- FDA | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
